EGFR and neoplasm: While osimertinib inhibited the viability of all EGFR-mutated NSCLC cell lines tested in a dose-dependent manner, the IC50 (half-maximum inhibitory concentration) values were lower in AXL-low-expressing tumor cell lines compared to the AXL-high-expressing tumor cell lines.